# LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

> **NCT05518357** · PHASE1 · COMPLETED · sponsor: **Hebei Yanda Ludaopei Hospital** · enrollment: 2 (actual)

## Conditions studied

- Relapsed/Refractory Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** LILRB4 STAR-T

## Key facts

- **NCT ID:** NCT05518357
- **Lead sponsor:** Hebei Yanda Ludaopei Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-24
- **Primary completion:** 2022-11-15
- **Final completion:** 2022-11-15
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2023-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05518357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05518357, "LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05518357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*